Biodesix Strengthens Financial Position With Equity Issuance And Amendment To Term Loan

Published by
The Street

By Business Wire Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced the sale of 3,756,994 common shares on December 30, 2021 in an at-the-market offering that raised approximately $16.3 million in gross proceeds to fund repayment of its existing term loan. In addition, the Company entered into a Second Amendment to its $30 million 2021 Term Loan (“Second Amendment”) on December 31, 2021, which includes modifications to certain restrictive financial covenants to provide the Company additional financial flexibility over the n…

Read More

See also  'Right to be forgotten': Israel firm promises to purge digital footprint

Leave a Reply